Clariget Od 500mg Extended Release Tablet

Страна: Філіппіни

мова: англійська

Джерело: FDA (Food And Drug Administration)

Активний інгредієнт:

Clarithromycin

Доступна з:

Getz Pharma (Phils.), Inc.

ІПН (Міжнародна Ім'я):

Clarithromycin

Дозування:

500mg

Фармацевтична форма:

Extended Release Tablet

Одиниць в упаковці:

Alu-Alu Blister Pack x 5's (Box of 5's), Alu-Alu Blister pack x 10's (Box of 5's)

Виробник:

Getz Pharma (Private) Limited, Pakistan

Терапевтична области:

Antibiotic

Терапевтичні свідчення:

For treatment of pharyngitis/tonsillitis; acute maxillary sinusitis; acute bacterial exacerbation of chronic bronchitis; community-acquired pneumonia; uncomplicated skin and skin structure infections; Helicobacter pylori and duodenal ulcer disease when used in combination with amoxicillin and lansoprazole or omeprazole; H. pylori and active duodenal ulcer when used in combination with omeprazole or ranitidine bismuth citrate; prevention of disseminated MAC disease in patients with advanced HIV infection; treatment of disseminated mycobacterial infections caused by M. avium or Mycobacterium intracellulare .

Дата Авторизація:

2019-12-19

Характеристики продукта

Rashes and Stevens-Johnson syndrome has also been reported. Transient
CNS effects include anxiety, dizziness, insomnia, hallucinations and
confusion.
Hypoglycemia, thrombocytopenia, interstitial nephtiris, renal failure,
hearing loss, glossitis, stomatitis, oral monilla and tongue
discoloration,
tooth discoloration, hepatitis, hepatic failure, jaundice,
electrocardiogram
QT prolongation, Torsades de Pointes have also been reported with
clarithromycin therapy.
_Adverse laboratory changes_
Changes in laboratory parameters are:
Hepatic: Elevated SGPT (ALT), SGOT (AST), GGT, alkaline phosphates,
LDH, bilirubin.
Hematologic: Decreased WBC, elevated prothrombin time.
Renal: Elevated BUN, elevated serum creatinine.
PRECAUTIONS
-
Long term use may, as with other antibiotics, result in colonization
with increased numbers of non-susceptible bacteria and fungi. If
superinfections occur, appropriate therapy should be instituted.
-
Caution should be exercised in administering clarithromycin to
patients with impaired hepatic function and to patients with moderate
renal function.
-
Caution should also be paid to the possibility of cross-resistances
between clarithromycin and other macrolide drugs, as well as
lincomycin and clindamycin.
-
Pseudomembranous colitis has been reported with nearly all anti-
bacterial agents, including clarithromycin, and may range in severity
from mild to life threatening. Therefore it is important to consider
this diagnosis in patients who have diarrhea subsequent to the
administration of antibacterial agents. After the diagnosis of
pseudomembranous colitis has been established, therapeut
ic
measures should be initiated.
-
Safety and effectiveness of clarithromycin in pediatric patients under
6 months of age have not been established.
-
It may cause exacerbation of symptoms of myasthenia gravis.
_Pregnancy_
Clarithromycin should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus. It should not be
prescribed
particularly during the first 3 months of pregn